Capmatinib

Search with Google Search with Bing

Information
Drug Name
Capmatinib
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION C Predictive Supports Sensitivity/Response Somatic 3 25971938 Detail
cancer MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION D Predictive Supports Sensitivity/Response Somatic 3 25971938 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A patient with MET c.3028+1G>T mutation (METex14) ... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
MET exon 14 skipping was modelled in vitro by expr... MET MET EXON 14 SKIPPING MUTATION MET EXON 14 SKIPPING MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03784014 Active, not recruiting Phase 3 Molecular Profiling of Advanced Soft-tissue Sarcomas October 19, 2019 October 2025
NCT04926831 Active, not recruiting Phase 2 Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC August 10, 2022 August 6, 2026
NCT04677595 Active, not recruiting Phase 2 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation May 17, 2021 December 31, 2025
NCT04741789 Available Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)
NCT05154344 Completed RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) November 29, 2021 February 1, 2022
NCT04427072 Completed Phase 3 Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation September 25, 2020 October 31, 2023
NCT02795429 Completed Phase 1/Phase 2 Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC June 15, 2016 June 24, 2021
NCT02414139 Completed Phase 2 Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) June 11, 2015 May 16, 2023
NCT05675683 Completed Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib October 1, 2021 December 31, 2021
NCT03647488 Completed Phase 2 Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer December 26, 2018 September 7, 2020
NCT06054191 Not yet recruiting Phase 2 Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations February 1, 2024 March 1, 2027
NCT05642572 Recruiting Phase 2 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) May 5, 2023 May 31, 2027
NCT02813135 Recruiting Phase 1/Phase 2 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors August 3, 2016 August 2027
NCT05243641 Recruiting Phase 1/Phase 2 Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test August 18, 2022 December 31, 2028
NCT03040973 Recruiting Phase 2 Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone July 4, 2017 July 30, 2027
NCT05488314 Recruiting Phase 1/Phase 2 A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer December 13, 2022 August 22, 2026
NCT05703516 Recruiting A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea June 12, 2023 October 31, 2024
NCT05135845 Suspended Phase 2 Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma March 22, 2022 October 2025
NCT02335944 Terminated Phase 1/Phase 2 Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. January 13, 2015 November 10, 2020
NCT04139317 Terminated Phase 2 Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% January 22, 2020 February 7, 2023
NCT03742349 Terminated Phase 1 Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). January 31, 2019 February 6, 2023
NCT04816214 Terminated Phase 3 Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy September 22, 2021 December 27, 2022
NCT05435846 Terminated Phase 1 Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation August 10, 2022 May 31, 2024
NCT02587650 Terminated Phase 2 Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma March 26, 2015 July 12, 2018
NCT04323436 Terminated Phase 2 Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations August 19, 2020 January 26, 2023
NCT03693339 Unknown status Phase 2 Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation October 30, 2018 June 30, 2022
NCT04460729 Withdrawn Phase 2 A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases November 11, 2020 November 17, 2023
NCT05567055 Withdrawn Phase 2 Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations October 3, 2023 September 2028